SCYNEXIS Phase 1 SCY-770 Data Clears Path to Q4 Trial

SCYNEXIS (NASDAQ: SCYX) announced on 6 October 2026 that its Phase 1 study of SCY-770, an oral direct AMPK activator for autosomal dominant polycystic kidney disease, completed with the drug well tolerated in healthy adults at doses above those previously tested. The trial enrolled 25 participants across three cohorts, including 750 mg once daily and 500 mg twice daily for seven days. The company said its Phase 2 proof-of-concept study in ADPKD patients remains on track to begin in the fourth quarter of 2026.

Context — why this matters now

The reported result is a dose-ceiling read, not a new efficacy claim. SCYNEXIS said SCY-770 was well tolerated across all cohorts and that its safety profile was consistent with prior clinical experience, which the company describes as spanning roughly 300 participants across multiple trials to date.

The company's own framing ties the study to dose selection, not to a clinical endpoint. Todd Minga, M.D., SCYNEXIS's SVP of Research and Development, said the pharmacokinetic and safety data "provide important insights to support dose selection" for the Phase 2 study, and that the company was encouraged by the tolerability profile across the doses studied.

That distinction matters because ADPKD has exactly one approved therapy, Jynarque (tolvaptan). The company said tolvaptan generated approximately $1.5 billion in U.S. sales in 2024 despite limited patient uptake tied to safety, tolerability and monitoring requirements. The unmet need the company cites is therefore about tolerability as much as about efficacy.

The U.S. prevalence figure the company gives is 140,000 patients, with roughly 6,000 new diagnoses each year. More than half of patients reach end-stage renal failure by age 60 and require dialysis or transplant, per the company's description of the disease.

SCY-770 holds Orphan Drug Designation from the U.S. Food and Drug Administration for ADPKD. SCYNEXIS is also advancing SCY-247 for invasive fungal diseases and has licensed BREXAFEMME (ibrexafungerp tablets) to GSK.

Data — what the numbers show

The trial design is the concrete deliverable. The initial cohort received a single 500 mg dose under fed and fasted conditions. Subsequent cohorts received either 750 mg once daily or 500 mg twice daily, or placebo, for seven days.

Parameter	Phase 1 detail
Participants enrolled	25 healthy adults
Cohorts	3
Highest daily exposure tested	750 mg once daily
Repeat dosing	7 days
Prior SCY-770 exposure	~300 participants across trials

Before this study, the company describes the tested range as lower, which is why the 750 mg and 500 mg twice-daily arms represent a step up rather than a repeat of earlier work.

The pharmacokinetic readout spans this study and prior studies, and the company said that combined dataset will inform Phase 2 dose selection. SCYNEXIS did not disclose individual adverse-event rates, plasma exposure values, half-life, or bioavailability figures.

For scale, the company's ADPKD prevalence estimate of 140,000 U.S. patients sits against a single approved competitor that booked roughly $1.5 billion in U.S. sales in 2024. No efficacy comparison between SCY-770 and tolvaptan exists in the report, because this study enrolled healthy participants rather than patients.

Analysis — what it means for markets and sectors

The read matters most for the risk profile of a clinical-stage balance sheet. A tolerability failure at higher doses would have compressed the addressable dose range available for a chronic, years-long kidney therapy, where patients take drug daily. Clearing 750 mg once daily and 500 mg twice daily keeps both a once-daily and a twice-daily path open into Phase 2.

The mechanistic pitch is what distinguishes SCY-770 from the incumbent. The company said AMPK activation targets multiple pathways implicated in cyst growth and fluid secretion, including mTOR and cAMP signaling, and is associated with reductions in inflammation and fibrosis plus improved cellular metabolism.

That multi-pathway claim is a hypothesis entering Phase 2, not a demonstrated effect. The limitation is structural: healthy-volunteer data cannot show whether AMPK activation slows cyst growth or preserves kidney function, and the report gives no biomarker or imaging endpoint from this study.

Positioning follows the calendar. The stock's near-term narrative now rests on whether the Phase 2 proof-of-concept study starts in the fourth quarter of 2026 as guided, and the company flagged a specific risk in its own forward-looking statements: it may not reach alignment with the FDA on the planned Phase 2 design on the anticipated timeline, or at all. For a company with one approved asset licensed to GSK and a second clinical program in antifungals, SCY-770's read-through sits with investors pricing rare-disease kidney assets against tolvaptan's commercial ceiling.

Outlook — what to watch next

Two dated catalysts anchor the next stretch. The first is initiation of the Phase 2 proof-of-concept study in ADPKD patients, which the company still targets for the fourth quarter of 2026. The second is FDA alignment on that study's design, which the company lists as a risk to the timeline rather than a completed step.

SCYNEXIS did not disclose the size, endpoint, duration or geographic footprint of the planned Phase 2 study, and it did not give a date for a data readout. Those gaps are the items a dose-selection announcement leaves open.

Investors watching the name should also track disclosure of the population pharmacokinetic modeling the company said will support dose selection. If that modeling is published alongside the Phase 2 start, it will show which of the tested regimens was carried forward. No price levels, moving averages or analyst targets appear in the report.

Frequently Asked Questions

What does the SCY-770 Phase 1 result mean for retail investors?

It removes one specific risk from the program: the drug was tolerated at doses above those previously evaluated, keeping a once-daily 750 mg and a twice-daily 500 mg option open for Phase 2. It does not establish efficacy. SCYNEXIS remains a clinical-stage company, and the report gives no revenue, cash position or earnings figures tied to SCY-770.

What happens next for SCYNEXIS and SCY-770?

The company said the Phase 2 proof-of-concept study in ADPKD patients remains on track to initiate in the fourth quarter of 2026, with dose selection informed by pharmacokinetic data from this and prior studies. SCYNEXIS also disclosed a risk that it may not reach alignment with the FDA on the planned Phase 2 design on that timeline.

Why did SCYNEXIS test higher doses of SCY-770?

Dose selection for a chronic kidney therapy depends on finding the highest exposure patients can tolerate over long treatment periods. The Phase 1 study pushed to 750 mg once daily and 500 mg twice daily for seven days, above the prior range, so the company could characterize safety and pharmacokinetics before committing a regimen to the patient study.

Bottom Line

SCYNEXIS cleared the tolerability bar at higher SCY-770 doses, leaving Q4 2026 Phase 2 initiation and FDA design alignment as the next binary checkpoints.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.